INNOVATE Corp.: management transactions · United States · SEC (Form 4)

About INNOVATE Corp.

INNOVATE Corp. is a United States-based company listed on the NYSE under the ticker VATE, with its principal executive offices in New York, New York. The company was incorporated in 1994 and operates as a diversified holding company rather than a pure-play industrial manufacturer. For investors, the key point is that INNOVATE should be viewed as a special-situations holding structure: equity value is driven not only by operating performance at the subsidiary level, but also by leverage, refinancing capacity, and asset portfolio decisions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006837/000100683726000014/vate-20251231.htm)) The largest and most important operating platform is Infrastructure, centered on DBM Global Inc. DBM Global is a fully integrated construction company providing construction and professional services through businesses such as Schuff Steel Company, Banker Steel, and GrayWolf Industrial. These operations serve a broad mix of commercial and industrial end markets, with a core focus on structural steel and specialized construction work. This segment is the main revenue engine of the group and ties INNOVATE closely to the U.S. industrial construction cycle. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006837/000100683726000014/vate-20251231.htm)) INNOVATE also maintains a Life Sciences platform through Pansend Life Sciences, LLC, which is focused on healthcare and biotechnology product development. One of the more visible portfolio companies is R2 Technologies, headquartered in Dublin, California. R2 develops aesthetic medical and non-medical devices built around its CryoAesthetics™ technologies and Glacial® platform, which use precision cooling to improve skin tone and reduce inflammation and discoloration. Founded in 2014, R2 has brought products such as Glacial Rx, Glacial Spa, and Glacial fx into commercialization across multiple geographies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006837/000100683726000014/vate-20251231.htm)) A smaller Spectrum segment remains part of the portfolio, historically linked to broadcasting/media-related assets. Even so, the overall corporate profile is clearly weighted toward industrial construction and, to a lesser extent, medtech and other non-core assets. INNOVATE itself states that it is a holding company whose principal source of cash comes from distributions from its subsidiaries. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006837/000100683726000014/vate-20251231.htm)) From a competitive standpoint, INNOVATE is not a large-cap diversified industrial leader. Instead, it operates as a niche, asset-backed group in fragmented and competitive markets. DBM Global’s technical capabilities and project execution are potential strengths, while the Life Sciences portfolio offers some longer-dated optionality. Against that, the company’s financial structure is a central consideration: debt maturities, covenant pressure, and potential divestitures remain material strategic variables. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006837/000100683726000014/vate-20251231.htm)) Recent filings and disclosures show that the company released its full-year 2025 results on March 26, 2026 and its first-quarter 2026 results on May 14, 2026. Those filings also highlight ongoing liquidity stress and capital-structure management as major themes for the year ahead. For French-speaking investors, VATE is best understood as an NYSE-listed U.S. holding company where operational execution, asset monetization, and balance-sheet repair are tightly linked. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006837/000100683726000013/vate-20260326.htm))